Evidence map›Paper›PMID 38172128›Full record

ArticleNPJ Parkinson's disease2024

Transcriptomic profiling of early synucleinopathy in rats induced with preformed fibrils.

Joseph R Patterson, Joseph Kochmanski, Anna C Stoll, Michael Kubik, Christopher J Kemp, Megan F Duffy, Kajene Thompson, Jacob W Howe, Allyson Cole-Strauss, Nathan C Kuhn and 9 more

Open access · goldAbstract read
In one paragraph

Article in NPJ Parkinson's disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 1 country.

Joseph R PattersonDepartment of Translational Science and Molecular Medicine, Michigan State University, Grand Rapids, MI, USA. patte401@msu.edu.ORCID http://orcid.org/0000-0003-0926-7396
Joseph KochmanskiDepartment of Translational Science and Molecular Medicine, Michigan State University, Grand Rapids, MI, USA.ORCID http://orcid.org/0000-0002-8472-3032
Anna C StollDepartment of Translational Science and Molecular Medicine, Michigan State University, Grand Rapids, MI, USA.
Michael KubikDepartment of Translational Science and Molecular Medicine, Michigan State University, Grand Rapids, MI, USA.
Christopher J KempDepartment of Translational Science and Molecular Medicine, Michigan State University, Grand Rapids, MI, USA.
Megan F DuffyDepartment of Translational Science and Molecular Medicine, Michigan State University, Grand Rapids, MI, USA.ORCID http://orcid.org/0000-0003-0094-0900
Kajene ThompsonDepartment of Translational Science and Molecular Medicine, Michigan State University, Grand Rapids, MI, USA.
Jacob W HoweDepartment of Translational Science and Molecular Medicine, Michigan State University, Grand Rapids, MI, USA.ORCID http://orcid.org/0000-0001-5510-1018
Allyson Cole-StraussDepartment of Translational Science and Molecular Medicine, Michigan State University, Grand Rapids, MI, USA.
Nathan C KuhnDepartment of Translational Science and Molecular Medicine, Michigan State University, Grand Rapids, MI, USA.
Kathryn M MillerDepartment of Translational Science and Molecular Medicine, Michigan State University, Grand Rapids, MI, USA.
Seth NelsonDepartment of Translational Science and Molecular Medicine, Michigan State University, Grand Rapids, MI, USA.
Christopher U OnyekpeDepartment of Translational Science and Molecular Medicine, Michigan State University, Grand Rapids, MI, USA.
John S BeckDepartment of Translational Science and Molecular Medicine, Michigan State University, Grand Rapids, MI, USA.
Scott E CountsDepartment of Translational Science and Molecular Medicine, Michigan State University, Grand Rapids, MI, USA.
Alison I BernsteinDepartment of Translational Science and Molecular Medicine, Michigan State University, Grand Rapids, MI, USA.ORCID http://orcid.org/0000-0002-5589-4318
Kathy Steece-CollierDepartment of Translational Science and Molecular Medicine, Michigan State University, Grand Rapids, MI, USA.
Kelvin C LukCenter for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-6591-6269
Caryl E SortwellDepartment of Translational Science and Molecular Medicine, Michigan State University, Grand Rapids, MI, USA.
Michigan State University · USRutgers, The State University of New Jersey · USUniversity of Pennsylvania · US

Funding

Integrative Pharmacological Sciences Training Program (IPSTP)T32GM142521 · NIGMS · MICHIGAN STATE UNIVERSITY · PI ANNE M. DORRANCE, Gina Marie Leinninger · 2021 to 2026
$2.4M
The Rat Pre-Formed Alpha-Synuclein Fibril Model of Parkinson's DiseaseR33NS099416 · NINDS · MICHIGAN STATE UNIVERSITY · PI SORTWELL, CARYL E · 2018 to 2019
$899k
Synucleinopathy triggered neuroinflammationR21NS111333 · NINDS · MICHIGAN STATE UNIVERSITY · PI SORTWELL, CARYL E · 2019 to 2019
$442k
The Rat Pre-Formed Alpha-Synuclein Fibril Model of Parkinson's DiseaseR21NS099416 · NINDS · MICHIGAN STATE UNIVERSITY · PI SORTWELL, CARYL E · 2017 to 2017
$398k
NIGMS NIH HHS T32 GM142521NINDS NIH HHS R21 NS099416NINDS NIH HHS R21 NS111333NINDS NIH HHS R33 NS099416
6 · The paper itself

Abstract

Examination of early phases of synucleinopathy when inclusions are present, but long before neurodegeneration occurs, is critical to both understanding disease progression and the development of disease modifying therapies. The rat alpha-synuclein (α-syn) preformed fibril (PFF) model induces synchronized synucleinopathy that recapitulates the pathological features of Parkinson's disease (PD) and can be used to study synucleinopathy progression. In this model, phosphorylated α-syn (pSyn) inclusion-containing neurons and reactive microglia (major histocompatibility complex-II immunoreactive) peak in the substantia nigra pars compacta (SNpc) months before appreciable neurodegeneration. However, it remains unclear which specific genes are driving these phenotypic changes. To identify transcriptional changes associated with early synucleinopathy, we used laser capture microdissection of the SNpc paired with RNA sequencing (RNASeq). Precision collection of the SNpc allowed for the assessment of differential transcript expression in the nigral dopamine neurons and proximal glia. Transcripts upregulated in early synucleinopathy were mainly associated with an immune response, whereas transcripts downregulated were associated with neurotransmission and the dopamine pathway. A subset of 29 transcripts associated with neurotransmission/vesicular release and the dopamine pathway were verified in a separate cohort of males and females to confirm reproducibility. Within this subset, fluorescent in situ hybridization (FISH) was used to localize decreases in the Syt1 and Slc6a3 transcripts to pSyn inclusion-containing neurons. Identification of transcriptional changes in early synucleinopathy provides insight into the molecular mechanisms driving neurodegeneration.

Identifiers

PMID38172128
PMCPMC10764951
OpenAlexW4390571975

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.